These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8564389)

  • 21. Pharmacology of the hypoglycaemic sulphonylurea gliquidone. III. Conformational analysis.
    Lins L; Brasseur R; Malaisse WJ
    Pharmacol Res; 1996; 34(1-2):9-10. PubMed ID: 8981549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a new hypoglycemic agent A-4166 on glucose metabolism in rat adipocytes and muscle tissues.
    Macho L; Ficková M; Zórad S; Seböková E; Klimes I
    Gen Physiol Biophys; 1999 Sep; 18(3):293-303. PubMed ID: 10703745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-releasing activity of a series of phenylalanine derivatives.
    Tang L; Yu J; Wu H; Fan H; Yang Y; Ji R
    Eur J Med Chem; 2008 Sep; 43(9):1997-2003. PubMed ID: 18191001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of new hypoglycemic agent A-4166 on lipolysis and lipogenesis in rat adipocytes.
    Macho L; Fickova M; Zorad S; Sebokova E; Klimes I
    Endocr Regul; 2000 Sep; 34(3):119-26. PubMed ID: 11074662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
    Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
    Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of the hydrophobic energy: structural determination of a hypoglycemic drug of the meglitinide family by nuclear magnetic resonance and molecular modeling.
    Lins L; Brasseur R; Malaisse WJ; Biesemans M; Verheyden P; Willem R
    Biochem Pharmacol; 1996 Oct; 52(8):1155-68. PubMed ID: 8937422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitiglinide. KAD 1229.
    Drugs R D; 1999 Aug; 2(2):114-5. PubMed ID: 10820654
    [No Abstract]   [Full Text] [Related]  

  • 29. Nateglinide may increase high-molecular weight adiponectin in type 2 diabetic patients with hypoadiponectinemia.
    Iwase M; Iino K; Doi Y; Asano T; Iida M
    Diabetes Res Clin Pract; 2008 Dec; 82(3):e19-22. PubMed ID: 18849086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elimination of metformin-croscarmellose sodium interaction by competition.
    Huang WX; Desai M; Tang Q; Yang R; Vivilecchia RV; Joshi Y
    Int J Pharm; 2006 Mar; 311(1-2):33-9. PubMed ID: 16426778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ionophoretic property of hypoglycemic sulfonylureas: competition between H+ and Ca2+.
    Deleers M; Couturier E; Mahy M; Gelbcke M; Malaisse WJ
    Ann Endocrinol (Paris); 1981; 42(3):297-9. PubMed ID: 7316466
    [No Abstract]   [Full Text] [Related]  

  • 32. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
    Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
    Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of tritiated S21403 to an artificial phospholipid bilayer.
    Malaisse WJ; Dard-Brunelle B
    Res Commun Mol Pathol Pharmacol; 1999 Mar; 103(3):269-74. PubMed ID: 10509738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase.
    Takahashi A; Nagashima K; Hamasaki A; Kuwamura N; Kawasaki Y; Ikeda H; Yamada Y; Inagaki N; Seino Y
    Diabetes Res Clin Pract; 2007 Sep; 77(3):343-50. PubMed ID: 17316868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The metabolism of the pancreatic beta-cells of mice in the presence of hypoglycaemic sulphonylureas.
    Westman S; Hellerström C
    Postgrad Med J; 1970 Dec; ():Suppl:28-31. PubMed ID: 5500514
    [No Abstract]   [Full Text] [Related]  

  • 37. Phospholipids as ionophores.
    Tyson CA; Vande Zande H; Green DE
    J Biol Chem; 1976 Mar; 251(5):1326-32. PubMed ID: 1254569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithyroid effect of glibenclamide on the rat and mouse.
    Cheema AM; Matty AJ; Bromage NR
    Postgrad Med J; 1970 Dec; ():Suppl:24-7. PubMed ID: 5500513
    [No Abstract]   [Full Text] [Related]  

  • 39. [Preparation of optically active succinic acid derivatives. III. Regioselective condensation reactions of optically active 2-substituted succinic acids with diimidazolide].
    Yamaguchi T; Yanagi T; Hokari H; Mukaiyama Y; Kamijo T; Yamamoto I
    Yakugaku Zasshi; 1998 Jun; 118(6):248-55. PubMed ID: 9629061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of glibenclamide on glucose uptake in the isolated rat diaphragm.
    Standing VF; Foy JM
    Postgrad Med J; 1970 Dec; ():Suppl:16-20. PubMed ID: 5500511
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.